Skip to main content
HABA LABORATORIES, INC. logo

HABA LABORATORIES, INC. — Investor Relations & Filings

Ticker · 4925 ISIN · JP3765130004 T Manufacturing
Open in API
Filings indexed 66 across all filing types
Latest filing 2024-06-24 Governance Information
Country JP Japan
Listing T 4925

About HABA LABORATORIES, INC.

http://www.haba.com/

HABA LABORATORIES, INC. is a company that develops, manufactures, and distributes natural cosmetics, quasi-drugs, and nutritional supplements. The company's product line includes skincare, hair care, and body care items. Its core philosophy, reflected in the name HABA (an acronym for "Health Aid, Beauty Aid"), is to create additive-free products that maximize the skin's natural healing power by providing only essential ingredients. The company sells its products through multiple channels, including online shopping, direct retail stores, and wholesale distribution to drug and variety stores in Japan and internationally.

Recent filings

Filing Released Lang Actions
内部統制報告書－第41期(2023/04/01－2024/03/31)
Governance Information Classification · 100% confidence The document explicitly states in the header section (【提出書類】) that it is an "内部統制報告書" (Internal Control Report). The legal basis cited is Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項), which mandates the filing of an Internal Control Report. The content discusses the framework, scope, criteria, and conclusion regarding the effectiveness of internal controls over financial reporting as of the fiscal year-end (March 31, 2024). This directly corresponds to the definition of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although 'Internal Control Report' is a specific type of assurance/audit-related filing. Given the provided categories, 'AR' (Audit Report / Information) is the closest fit for a formal report detailing internal control effectiveness assessment, as it is not a full Annual Report (10-K) or a general Earnings Release (ER).
2024-06-24 Japanese
有価証券報告書－第41期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the standard annual financial filing required by the Financial Services Agency of Japan under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, management discussion, and business performance data for the fiscal year ending March 31, 2024. This corresponds to the 10-K equivalent in the provided classification schema. FY 2024
2024-06-24 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director, dated May 10, 2024. The filing reason explicitly states that it is submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related Cabinet Office Ordinance provisions because an event significantly impacting the company's financial condition, operating results, and cash flow has occurred. The content details the recognition of an impairment loss (減損損失) as an extraordinary loss for the fiscal year ended March 2024. This structure—a formal, timely disclosure of a significant, non-periodic financial event (impairment loss)—is characteristic of a Japanese 'Extraordinary Report' or 'Timely Disclosure Filing'. Among the provided codes, 'RNS' (Regulatory Filings) is the most appropriate general category for mandatory, non-standardized regulatory disclosures that don't fit the specific periodic reports (like 10-K or IR) or specific event types (like DIV or DIRS). Since this is a specific regulatory filing mandated by the FIEL for significant events, RNS serves as the best fit, although it is a specific type of filing in the Japanese context.
2024-05-10 Japanese
臨時報告書
Earnings Release Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is filed with the Kanto Local Finance Bureau (関東財務局長) on April 17, 2024. The filing reason explicitly states that an event significantly impacting the company's financial condition, operating results, and cash flow has occurred, necessitating submission under Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details the receipt of a dividend (剰余金の配当を受領) from a subsidiary, which is recognized as non-operating income (営業外収益). This structure—a formal, mandatory filing triggered by a specific financial event (like a large dividend receipt) that doesn't fit standard periodic reports (10-K, IR)—points towards a general regulatory disclosure. Since the event is a specific financial transaction (dividend receipt) and not a general announcement of a report, nor a change in management or capital structure, it falls best under the general regulatory filing category, as it is a specific disclosure required by law outside of the standard reporting cycle. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for specific, non-standard regulatory disclosures in this context, although 'DIV' (Notice of Dividend Amount) is related, this document is the *report* of receiving the dividend, not the *announcement* of the dividend itself, making RNS a safer general classification for this type of extraordinary filing. FY 2024
2024-04-17 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies a fiscal period ("第41期第３四半期（自2023年10月１日 至2023年12月31日）"). It also references compliance with the Financial Instruments and Exchange Act ("金融商品取引法令"). This structure strongly indicates a comprehensive financial report covering a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). The document is short and appears to be a confirmation or cover page related to the filing, but the core subject matter is the quarterly financial report itself, making 'IR' the most appropriate classification over 'RPA' or 'RNS'.
2024-02-14 Japanese
四半期報告書－第41期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for HABA Laboratories, Inc. covering the third quarter of the 41st fiscal period (ending December 31, 2023). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management's analysis of financial conditions and operating results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.